Strategies to Overcome Challenges in Commercializing Treatments for Rare Diseases
By Kelly Cockerill, Vice President, Marsha Pelletier, Director, Philippe De Gaiffier, Consultant, and Carrie Jones, Partner
Rare Disease Day serves as a reminder of the ongoing collaborative effort in the healthcare industry to bring valuable new treatments for the over 300MM global rare disease patients.
Despite the rapidly advancing science and established unmet need for patients, rare disease drug manufacturers face several unique challenges when commercializing new products.
Health Advances, as a strategic healthcare and life sciences consulting firm, helps rare disease drug developers make smart decisions that will best position their products for broad patient access.
In our 30 years of work across the rare disease industry, we’ve identified several key success factors:
Interested in some of these examples? Please reach out to us or follow our blog so you don’t miss our future deep dives on these topics above and many more. https://healthadvancesblog.com
Contact
Carrie Jones cjones@healthadvances.com, Partner leads Health Advances’ Rare and Orphan Disease Practice.
###
Related Insights
Whitepaper
How real-world data is powering rare disease research Part 2. RWD advances in Europe
Apr 18, 2025
Blog
Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence
Aug 10, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
What Do the Next 10 Years Hold for CRISPR?
Jul 27, 2022
Video
A Life in a Day
Jul 28, 2022
Blog
Taking a Proactive Approach to Post-Launch Patient Accessibility in Strategic Planning
Aug 4, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Video
Impact of Innovation on Market Access for Wound Care Products
Jul 14, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change
Aug 24, 2022
Related Insights
Whitepaper
How real-world data is powering rare disease research Part 2. RWD advances in Europe
Apr 18, 2025
Blog
Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence
Aug 10, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
What Do the Next 10 Years Hold for CRISPR?
Jul 27, 2022
Video
A Life in a Day
Jul 28, 2022
Blog
Taking a Proactive Approach to Post-Launch Patient Accessibility in Strategic Planning
Aug 4, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Video
Impact of Innovation on Market Access for Wound Care Products
Jul 14, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change
Aug 24, 2022